Why the study?
Paclitaxel causes debilitating peripheral neuropathy that may limit chemotherapy, and the study aimed to evaluate vitamin B prophylaxis to reduce its severity, especially in diabetic patients, along with gabapentin needs and disease response.
Does vitamin B prophylaxis reduce the severity of paclitaxel-induced peripheral neuropathy in adult ovarian cancer patients?
Population
146 adult ovarian cancer patients receiving paclitaxel
Comparison
Vitamin B prophylaxis before paclitaxel vs vitamin B upon CIPN
Design
Randomized clinical trial
Follow-up
18 weeks
Authors
Loading...
Provides low-cost prophylaxis to enhance paclitaxel tolerance in ovarian cancer; confirms vitamin B efficacy in RCT and supports broader oncology research.
Does vitamin B prophylaxis reduce the severity of paclitaxel-induced peripheral neuropathy in adult ovarian cancer patients?
Vitamin B prophylaxis significantly reduces paclitaxel-induced peripheral neuropathy severity and the need for gabapentin in ovarian cancer patients, minimizing dose reductions and improving progression-free survival.
Haggagy et al. (2026) studied this question.